Form 4: Hims & Hers Health Chief Medical Officer Reports Stock Transactions
SEC Form 4 Filing
Chief Medical Officer of Hims & Hers Health, Patrick Harrison Carroll, reports the vesting and sale of restricted stock units to cover tax obligations.
Summary
- On September 13, 2024, Patrick Harrison Carroll, the Chief Medical Officer of Hims & Hers Health, Inc., reported transactions involving Class A Common Stock.
- Carroll acquired 12,989 shares through the vesting of Restricted Stock Units (RSUs).
- He disposed of 3,811 shares to cover tax withholding obligations at a price of $16.57 per share.
- Following these transactions, Carroll directly owns 211,941 shares of Class A Common Stock.
- He also holds 73,338 RSUs from one grant and 67,754 RSUs from another grant, both of which are subject to service-based vesting requirements.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment, as it primarily reflects compensation and tax-related activities.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be monitored by investors for insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading.
- Companies like Teladoc Health, GoodRx, and Amazon also have similar insider transaction disclosures, reflecting the common practice of stock-based compensation and related tax obligations.
- The vesting schedules and tax withholding practices described in this filing are typical for RSU grants in publicly traded companies.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they involve the vesting of previously granted equity and the sale of shares to cover tax obligations.
- The disclosure provides transparency to shareholders regarding insider transactions, which can influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| December 15, 2023 | 25% of one RSU grant vests. |
| March 15, 2024 | Quarterly vesting date for one RSU grant. |
| June 15, 2024 | First vesting date for another RSU grant and quarterly vesting date for one RSU grant. |
| September 13, 2024 | Date of stock transactions (RSU vesting and share disposal for tax obligations). |
| September 15, 2024 | Quarterly vesting date for one RSU grant. |
| September 17, 2024 | Date of signature for the Form 4 filing. |
| December 15, 2024 | Quarterly vesting date for both RSU grants. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.